Alefacept Intramuscular and Xpovio (80 MG Twice Weekly)
Determining the interaction of Alefacept Intramuscular and Xpovio (80 MG Twice Weekly) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: The use of alefacept with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids. MANAGEMENT: Patients receiving other immunosuppressive or myelosuppressive agents or phototherapy should not be treated with alefacept because of the possibility of excessive immunosuppression. The duration of the period following treatment with alefacept before one should consider starting other immunosuppressive therapy has not been evaluated. References "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA. CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18
Professional:GENERALLY AVOID: The use of alefacept with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.
MANAGEMENT: Patients receiving other immunosuppressive or myelosuppressive agents or phototherapy should not be treated with alefacept because of the possibility of excessive immunosuppression. The duration of the period following treatment with alefacept before one should consider starting other immunosuppressive therapy has not been evaluated.
- "Product Information. Amevive (alefacept)." Biogen, Cambridge, MA.
- CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18
Generic Name: alefacept
Brand name: Amevive
Synonyms: Alefacept (Intramuscular), Alefacept
Generic Name: selinexor
Brand name: Xpovio
Synonyms: Xpovio
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Alefacept Intramuscular-Xryliderm
- Alefacept Intramuscular-Xrylix
- Alefacept Intramuscular-Xtampza ER
- Alefacept Intramuscular-Xtandi
- Alefacept Intramuscular-Xtramins
- Alefacept Intramuscular-Xtrelus
- Xpovio (80 MG Twice Weekly)-Alemtuzumab
- Xpovio (80 MG Twice Weekly)-Alemtuzumab (Campath)
- Xpovio (80 MG Twice Weekly)-Alemtuzumab (Lemtrada)
- Xpovio (80 MG Twice Weekly)-Alemtuzumab Intravenous
- Xpovio (80 MG Twice Weekly)-Alenaze-D
- Xpovio (80 MG Twice Weekly)-Alendronate